A pivotal, phase III trial of AC-1204 in patients with Alzheimer's disease.
Phase of Trial: Phase III
Latest Information Update: 20 May 2016
At a glance
- Drugs AC 1204 (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- 20 May 2016 New trial record
- 01 May 2016 According to an Accera media release, this trial will be required for regulatory approval of the drug which company plans to initiate early next year. Data from NOURISH AD will inform the design of this study.